A bill moving through Congress would speed government approval of lower-cost generic copies of brand-name drugs. But Endo Health Solutions reportedly is lobbying to require generic drugmakers to pay for independent tests to confirm their products are equivalent. "It could be a strategy in order to delay generic entry or make generics more costly," says George Chressanthis of Temple's Fox School of Business. "The other issue is to ensure that [generic drugs on the market are] truly bio-equivalent."

Two separate Bloomberg stories on the economic slowdown's impact on President Obama's election hopes quoted Temple political scientist Christopher Wlezien. "Take the slope of the economy and that’s really a good indicator of what voters will do, how they evaluate presidents," said Wlezien, co-author of the forthcoming book The Timeline of Presidential Elections. "The state of the economy is not all that clear. What happens over the next four or five months is going to matter a lot to the president."